Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
This artificial RNA ligase has higher thermostability than natural RNA ligase
Subscribe To Our Newsletter & Stay Updated
